These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 26585594)

  • 1. Pan-Bcl-2 inhibitor Obatoclax is a potent late stage autophagy inhibitor in colorectal cancer cells independent of canonical autophagy signaling.
    Koehler BC; Jassowicz A; Scherr AL; Lorenz S; Radhakrishnan P; Kautz N; Elssner C; Weiss J; Jaeger D; Schneider M; Schulze-Bergkamen H
    BMC Cancer; 2015 Nov; 15():919. PubMed ID: 26585594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-Bcl-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells.
    Koehler BC; Scherr AL; Lorenz S; Elssner C; Kautz N; Welte S; Jaeger D; Urbanik T; Schulze-Bergkamen H
    PLoS One; 2014; 9(9):e106571. PubMed ID: 25192188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells.
    Huang S; Sinicrope FA
    Autophagy; 2010 Feb; 6(2):256-69. PubMed ID: 20104024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
    Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
    BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of MCL-1 by obatoclax sensitizes Sp2/0-Ag14 hybridoma cells to glutamine deprivation-induced apoptosis.
    Harnett CC; Abusneina A; Clément J; Gauthier ER
    Cell Biochem Funct; 2015 Jul; 33(5):334-40. PubMed ID: 26178811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autophagy blockade sensitizes the anticancer activity of CA-4 via JNK-Bcl-2 pathway.
    Li Y; Luo P; Wang J; Dai J; Yang X; Wu H; Yang B; He Q
    Toxicol Appl Pharmacol; 2014 Jan; 274(2):319-27. PubMed ID: 24321340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obatoclax, a Pan-BCL-2 Inhibitor, Downregulates Survivin to Induce Apoptosis in Human Colorectal Carcinoma Cells Via Suppressing WNT/β-catenin Signaling.
    Or CR; Huang CW; Chang CC; Lai YC; Chen YJ; Chang CC
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32150830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Akt and Bcl-2 inhibition induces cell-type specific modulation of apoptotic and autophagic signaling in castration resistant prostate cancer cell lines.
    Avsar Abdik E; Abdik H; Turan D; Sahin F; Berger MR; Kaleagasioglu F
    Mol Biol Rep; 2021 Dec; 48(12):7755-7765. PubMed ID: 34647221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK.
    McCoy F; Hurwitz J; McTavish N; Paul I; Barnes C; O'Hagan B; Odrzywol K; Murray J; Longley D; McKerr G; Fennell DA
    Cell Death Dis; 2010 Dec; 1(12):e108. PubMed ID: 21368880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OBATOCLAX and ABT-737 induce ER stress responses in human melanoma cells that limit induction of apoptosis.
    Wroblewski D; Jiang CC; Croft A; Farrelly ML; Zhang XD; Hersey P
    PLoS One; 2013; 8(12):e84073. PubMed ID: 24367627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.
    Peter B; Cerny-Reiterer S; Hadzijusufovic E; Schuch K; Stefanzl G; Eisenwort G; Gleixner KV; Hoermann G; Mayerhofer M; Kundi M; Baumgartner S; Sperr WR; Pickl WF; Willmann M; Valent P
    J Leukoc Biol; 2014 Jan; 95(1):95-104. PubMed ID: 24052572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
    Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M
    Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obatoclax, a Pan-BCL-2 Inhibitor, Targets Cyclin D1 for Degradation to Induce Antiproliferation in Human Colorectal Carcinoma Cells.
    Or CR; Chang Y; Lin WC; Lee WC; Su HL; Cheung MW; Huang CP; Ho C; Chang CC
    Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28035994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).
    Konopleva M; Watt J; Contractor R; Tsao T; Harris D; Estrov Z; Bornmann W; Kantarjian H; Viallet J; Samudio I; Andreeff M
    Cancer Res; 2008 May; 68(9):3413-20. PubMed ID: 18451169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCL-2 inhibitors sensitize therapy-resistant chronic lymphocytic leukemia cells to VSV oncolysis.
    Samuel S; Beljanski V; Van Grevenynghe J; Richards S; Ben Yebdri F; He Z; Nichols C; Belgnaoui SM; Steel C; Goulet ML; Shamy A; Brown D; Abesada G; Haddad EK; Hiscott J
    Mol Ther; 2013 Jul; 21(7):1413-23. PubMed ID: 23689597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
    Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP
    J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
    Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
    Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
    Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of in vitro antileukemic activity of obatoclax and ABT-737.
    Opydo-Chanek M; Mazur L
    Tumour Biol; 2016 Aug; 37(8):10839-49. PubMed ID: 26880588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.
    Lin X; Morgan-Lappe S; Huang X; Li L; Zakula DM; Vernetti LA; Fesik SW; Shen Y
    Oncogene; 2007 Jun; 26(27):3972-9. PubMed ID: 17173063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.